Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
A HagenbeekM van Glabbeke

Abstract

Interferon alfa has shown significant activity in patients with low-grade malignant non-Hodgkin's lymphoma (NHL). In 1985, we initiated a prospective randomized study in which the potential benefit of interferon alfa given as maintenance treatment was investigated after tumor load reduction was achieved with chemoradiotherapy in patients with advanced low-grade malignant non-Hodgkin's lymphoma. The study involved 347 patients with stage III or IV disease, 315 satisfying the eligibility criteria. All were treated with a regimen of cyclophosphamide, vincristine, and prednisone (CVP) given every 3 weeks for eight cycles. Thereafter, patients were eligible for iceberg irradiation. Finally, all patients were completely restaged, and responding and stable-disease patients were then randomized, 122 to interferon alfa-2a maintenance, 3 million U three times weekly for 1 year; and 120 to no further treatment. Seventy-nine percent of the patients response to CVP, ie, 45% complete remissions (CR) and 34% partial remissions (PR). In the group of randomized patients, the response rate after CVP plus or minus radiotherapy was 90%. As compared with control patients, patients in the interferon (IFN) maintenance group had a tendency toward a pr...Continue Reading

Citations

Sep 10, 2003·Current Opinion in Oncology·Jesús G Berdeja
Feb 3, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A Z S RohatinerT A Lister
Mar 2, 2011·Cancer Biotherapy & Radiopharmaceuticals·Robert O Dillman
Sep 11, 2012·Current Opinion in Oncology·Till M Seiler, Wolfgang Hiddemann
Mar 10, 2018·Expert Review of Hematology·Madeliene Parrott, Simon Rule
Jul 10, 1999·Current Opinion in Hematology·R G Bociek, J O Armitage
Oct 3, 1999·Current Opinion in Oncology·P McLaughlin
Jun 28, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R L M HaasH Bartelink
Jan 22, 2010·The Cochrane Database of Systematic Reviews·Paolo BaldoLorenzo Moja
Jan 22, 2011·Journal of the National Cancer Institute·Nicole SkoetzAndreas Engert
May 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D Cheson
Aug 9, 2001·Blood·C M MandigersUNKNOWN Interzol (South-East Netherlands Comprehensive Cancer Centers Cooperative Group)
Aug 21, 2007·Current Oncology Reports·Marinus H J van Oers
Jul 8, 2011·Current Opinion in Oncology·Anne-Sophie MichalletGilles Salles
Jun 13, 2000·Cancer Biotherapy & Radiopharmaceuticals·C A White
Jun 18, 2002·The Oncologist·Peter McLaughlin
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce A PetersonArlan J Gottlieb
Feb 28, 2007·Leukemia & Lymphoma·Koen van Besien, Harry Schouten
Mar 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard HochsterSandra J Horning
Feb 13, 2018·Statistical Methods in Medical Research·Jing ZhangRam Tiwari
Mar 31, 2010·Seminars in Hematology·Tarek Sousou, Jonathan Friedberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.